PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29742194-1	2018	Gemcitabine, a pyrimidine nucleoside analogue, is an oncologic agent used in the treatment of cutaneous T-cell lymphoma (CTCL).	gemcitabine	0-11	TSPY like 2	Homo sapiens	121-125	
11978140-16	2002	At the forefront of systemic chemotherapy development, pegylated liposomal doxorubicin, gemcitabine, and pentostatin appear to have the greatest potential for success in CTCL therapy.	gemcitabine	88-99	TSPY like 2	Homo sapiens	170-174	
16216001-1	2005	BACKGROUND: Based on the activity of gemcitabine in heavily pretreated patients with cutaneous T-cell lymphoma (CTCL), the objective of the current study was to determine the role of gemcitabine in the treatment of patients with advanced, untreated CTCL.	gemcitabine	37-48	TSPY like 2	Homo sapiens	112-116	
16216001-1	2005	BACKGROUND: Based on the activity of gemcitabine in heavily pretreated patients with cutaneous T-cell lymphoma (CTCL), the objective of the current study was to determine the role of gemcitabine in the treatment of patients with advanced, untreated CTCL.	gemcitabine	183-194	TSPY like 2	Homo sapiens	112-116	
16216001-9	2005	CONCLUSIONS: The results of the current Phase II study demonstrate the activity of gemcitabine as a single agent in untreated CTCL patients.	gemcitabine	83-94	TSPY like 2	Homo sapiens	126-130	
16216001-10	2005	Further studies using gemcitabine in combination, either contemporary or sequentially, with other drugs in patients with advanced stage, untreated CTCL are needed.	gemcitabine	22-33	TSPY like 2	Homo sapiens	147-151	
24136145-1	2013	BACKGROUND: Both gemcitabine and bexarotene are established single agents for the treatment of cutaneous T-cell lymphoma (CTCL).	gemcitabine	17-28	TSPY like 2	Homo sapiens	122-126	
26809303-1	2015	Gemcitabine, a pyrimidine nucleoside analogue, is gaining recognition as a potential therapeutic agent for advanced-stage and refractory cutaneous T-cell lymphoma (CTCL).	gemcitabine	0-11	TSPY like 2	Homo sapiens	164-168	
26809303-5	2015	This is the first report of the efficacy of gemcitabine for CTCL in Japan.	gemcitabine	44-55	TSPY like 2	Homo sapiens	60-64	
26809303-6	2015	Gemcitabine is well tolerated and is an effective monotherapy for CTCL.	gemcitabine	0-11	TSPY like 2	Homo sapiens	66-70	
25496219-2	2015	Gemcitabine, a pyrimidine analogue, has been reported to be efficacious in CTCL.	gemcitabine	0-11	TSPY like 2	Homo sapiens	75-79	
25496219-3	2015	Most of the studies published used gemcitabine as a single agent in treating advanced CTCL.	gemcitabine	35-46	TSPY like 2	Homo sapiens	86-90	
25496219-4	2015	Our small case series demonstrated that a combination of gemcitabine and vinorelbine induced partial remission in all four patients with refractory or advanced CTCL, although the effects were not sustained for a long duration (2-6 months).	gemcitabine	57-68	TSPY like 2	Homo sapiens	160-164	
24908331-2	2014	Among the several second-line and experimental drugs, gemcitabine could be considered one of the most suitable options for pretreated CTCL.	gemcitabine	54-65	TSPY like 2	Homo sapiens	134-138	
24908331-9	2014	This long-term update on the role of gemcitabine as a single agent in pretreated advanced-stage CTCL confirms this monotherapy as effective and safe.	gemcitabine	37-48	TSPY like 2	Homo sapiens	96-100	
19073526-8	2008	Even agents considered to be conventional chemotherapy, such as gemcitabine or pegylated liposomal doxorubicin, have demonstrated activity in CTCL at relatively lower doses with less myelosuppression.	gemcitabine	64-75	TSPY like 2	Homo sapiens	142-146	
19438862-4	2009	OBJECTIVES: We report a multicentre retrospective study of 23 patients who received gemcitabine for advanced-stage CTCL and emphasize the high incidence of serious unusual adverse events.	gemcitabine	84-95	TSPY like 2	Homo sapiens	115-119	
19438862-13	2009	CONCLUSIONS: Our study confirms the early efficacy of gemcitabine in advanced-stage CTCL.	gemcitabine	54-65	TSPY like 2	Homo sapiens	84-88